Reduced prevalence of arterial thrombosis in von Willebrand disease

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 5, 2013, Pages 845-854

  Sanders, Y V ^a   Eikenboom, J ^b   de Wee, E M ^a   van der Bom, J G ^b,c   Cnossen, M H ^a,d   Degenaar Dujardin, M E L ^e   Fijnvandraat, K ^f,j   Kamphuisen, P W ^g,j   Laros van Gorkom, B A P ^h   Meijer, K ^g   Mauser Bunschoten, E P ^i,r   Leebeek, F W G ^a   Kors, A ^k   Zweegman, S ^k   Goverde, G J ^l   Jonkers, M H ^l   Dors, N ^m   Nijziel, M R ⁿ   Tamminga, R Y J ^g   van der Linden, P W ^o   Ypma, P F ^p   Smiers, F J W ^b   Granzen, B ^q   Hamulyak K ^q   Brons, P ^h   de Goede Bolder, A ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e Netherlands Hemophilia Society   (Netherlands)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l AMPHIA HOSPITAL   (Netherlands)

^m CATHARINA HOSPITAL   (Netherlands)

ⁿ MÁXIMA MEDICAL CENTER   (Netherlands)

^o Infection and Immunology   (Netherlands)

^p HAGA HOSPITAL   (Netherlands)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Acute myocardial infarction; Cardiovascular disease; Ischemic stroke; Von Willebrand disease; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGE; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD GROUP O; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; UNSTABLE ANGINA PECTORIS; VON WILLEBRAND DISEASE;

EID: 84877915937     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12194     Document Type: Article

References (35)

1. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257-79.
2. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
3. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23: 1764-70.
4. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010; 41: 2151-6.
5. van Schie MC, de Maat MP, Isaacs A, van Duijn CM, Deckers JW, Dippel DW, Leebeek FW. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117: 1393-9.
6. van Schie MC, Wieberdink RG, Koudstaal PJ, Hofman A, Ikram MA, Witteman JC, Breteler MM, Leebeek FW, De Maat MP. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost 2012; 10: 550-6.
7. van Loon JE, Kavousi M, Leebeek FW, Felix JF, Hofman A, Witteman JC, de Maat MP. von willebrand factor plasma levels, genetic variations, and coronary heart disease in an older population. J Thromb Haemost 2012; 10: 1262-9.
8. Franchini M, Coppola A. Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management. Semin Thromb Hemost 2012; 38: 185-99.
9. de Wee EM, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom HCJ, Fijnvandraat K, de Goede-Bolder A, Laros-van Gorkom BAP, Meijer K, Raat H, Leebeek FWG, for the WiN study group. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.
10. de Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JC, Fijnvandraat K, De Goede-Bolder A, Laros-van Gorkom B, Ypma PF, Zweegman S, Meijer K, Leebeek FW. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost 2011; 106: 885-92.
11. de Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J, De Goede-Bolder A, Laros-van Gorkom BA, Meijer K, Hamulyak K, Nijziel MR, Fijnvandraat K, Leebeek FW, for the Wi Nsg. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108: 683-92.
12. Gommer AM, Poos MJJC. Prevalence, incidence and mortality according to age and gender. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM: http://www.nationaalkompas.nl Accessed 22 September 2011, 2010.
13. Central Bureau of Statistics. Permanent Research Living Situation (POLS) survey. Voorburg/Heerlen: CBS: http://statline.cbs.nl Accessed 22 September 2011, 2009.
14. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
15. de Wee EM, Ikram MK, Dippel DW, Leebeek FW. Transient focal cerebral ischaemia and bilateral pulmonary embolism after desmopressin treatment for von Willebrand's disease. Haemophilia 2008; 14: 1133-4.
16. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599-606.
17. van Loon JE, de Jaegere PP, Ulrichts H, van Vliet HH, de Maat MP, de Groot PG, Simoons ML, Leebeek FW. The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb Haemost 2011; 106: 165-71.
18. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011; 118: 757-65.
19. Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AH, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TP, Briet E. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
20. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
21. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
22. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-4.
23. Fuster V, Lie JT, Badimon L, Rosemark JA, Badimon JJ, Bowie EJ. Spontaneous and diet-induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis 1985; 5: 67-73.
24. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424-8.
25. Sramek A, Bucciarelli P, Federici AB, Mannucci PM, De Rosa V, Castaman G, Morfini M, Mazzucconi MG, Rocino A, Schiavoni M, Scaraggi FA, Reiber JH, Rosendaal FR. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004; 109: 740-4.
26. Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993; 70: 758-61.
27. Denis CV, Wagner DD. Insights from von Willebrand disease animal models. Cell Mol Life Sci 1999; 56: 977-90.
28. Fransen van de Putte DE, Fischer K, Pulles AE, Roosendaal G, Biesma DH, Schutgens RE, Mauser-Bunschoten EP. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res 2012; 130: 157-62.
29. van de Putte DE, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW, Meijer K, Roosendaal G, Schutgens RE, Mauser-Bunschoten EP. History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. Eur J Haematol 2012; 89: 336-9.
30. Rosendaal FR, Briet E, Stibbe J, van Herpen G, Leuven JA, Hofman A, Vandenbroucke JP. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525-30.
31. van de Putte DE, Fischer K, Makris M, Tait RC, Collins PW, Meijer K, Roosendaal G, Chowdary P, Schutgens RE, Mauser-Bunschoten EP. Increased prevalence of hypertension in haemophilia patients. Thromb Haemost 2012; 108: 750-5.
32. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis 2006; 21: 175-8.
33. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006; 116: 120-5.
34. Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia 2010; 16(Suppl. 3): 58-66.
35. Schutgens RE, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15: 952-8.